Interactive 3D MOA The MOA is based on preclinical data and provided for illustrative purposes only. ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; MOA, mechanism of action; SSc-ILD, systemic sclerosis-associated interstitial lung disease. Quicklinks Specialty Pharmacies Prescripti...
Trade Name:Ofev®/ Vargatef® MOA:Tyrosine kinase inhibitor Indication:Idiopathic pulmonary fibrosis (IPF); Non small cell lung cancer (NSCLC) In 2011, orphan drug designation was assigned in the U.S. and Japan for the treatment of idiopathic pulmonary fibrosis. In 2013, orphan drug designati...
Dosing Recommendations Adverse Reactions Management MOA Access, Support, and Resources Specialty Pharmacy Access Support Support Services Resources and Videos Forms Management and Support Materials Reprints Access VideosINDICATIONS OFEV is indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF...